However, new hope has emerged for metastatic melanoma patients since the clinical approval of monoclonal antibodies developed against immune checkpoints, such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in 2011 and, subsequently, programmed cell death protein-1 (PD-1) in 2014. Here, CTLA4 is linked to metastatic melanoma.